Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Clinical trial NCT04868877 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04868877
Sponsor: Merus B.V.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer Metastatic Gastric Cancer Esophageal Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma Colorectal Cancer

Start date: 2021-04-28
Primary completion: 2026-03-01
Enrollment: 194

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.